ALLO - Allogene Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALLO is currently covered by 13 analysts with an average price target of $10.75. This is a potential upside of $9.69 (914.15%) from yesterday's end of day stock price of $1.06.

Allogene Therapeutics's activity chart (see below) currently has 126 price targets and 125 ratings on display. The stock rating distribution of ALLO is 82.35% BUY and 17.65% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.74% with an average time for these price targets to be met of 78.4 days.

Highest price target for ALLO is $14, Lowest price target is $5, average price target is $8.6.

Most recent stock forecast was given by ASTHIKA GOONEWARDENE from TRUIST on 14-May-2025. First documented stock forecast 05-Nov-2018.

Currently out of the existing stock ratings of ALLO, 28 are a BUY (82.35%), 6 are a HOLD (17.65%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$8.77 (713.01%)

2 months 23 days ago
(14-May-2025)

2/10 (20%)

$9.05 (952.63%)

94

Buy

$9

$7.77 (631.71%)

$10

2 months 23 days ago
(14-May-2025)

0/3 (0%)

$8.05 (847.37%)

Buy

$7

$5.77 (469.11%)

$9

2 months 23 days ago
(14-May-2025)

2/9 (22.22%)

$6.05 (636.84%)

3

Buy

$8

$6.77 (550.41%)

$9

4 months 18 days ago
(19-Mar-2025)

0/10 (0%)

$6.31 (373.37%)

Buy

$14

$12.77 (1038.21%)

4 months 23 days ago
(14-Mar-2025)

1/3 (33.33%)

$12.06 (621.65%)

192

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALLO (Allogene Therapeutics) average time for price targets to be met?

On average it took 78.4 days on average for the stock forecasts to be realized with a an average price target met ratio 22.74

Which analyst has the current highest performing score on ALLO (Allogene Therapeutics) with a proven track record?

MARK BREIDENBACH

Which analyst has the most public recommendations on ALLO (Allogene Therapeutics)?

Mark Breidenbach has 1 price targets and 6 ratings on ALLO

Which analyst is the currently most bullish on ALLO (Allogene Therapeutics)?

Luca Issi with highest potential upside - $30.49

Which analyst is the currently most reserved on ALLO (Allogene Therapeutics)?

Dane Leone with lowest potential downside - -$0

Allogene Therapeutics in the News

Allogene Therapeutics updates ALPHA3 trial protocol following safety event

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotech company currently trading at $1.17 per share, announced Friday that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). According to InvestingPro analysis, the company maintains a strong liquidity...

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion ArmUnplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rate and Safety ProfileALPHA3 Study...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?